North Shore Therapeutics develops digital solutions for psychiatric illnesses that have no effective treatment options.

Cognoa is developing digital products intended to support healthcare providers in expediting diagnosis with the goal of improving access to timely intervention for children and families, starting with autism spectrum disorder (ASD).

We are developing digital diagnostic and therapeutic products with the goal of enabling earlier and more equitable care for behavioral health conditions.

Despite major advances in pharmacotherapy, there are still significant unmet needs with no effective treatments for some SMI symptoms. The FDA has embraced “software as a medical device” enabling a path for clinically validated evidence-based digital therapeutics for psychiatry.1

Consumer-based mobile technology has advanced to allow for promising digital treatments for mental illness.

We are committed to developing, creating, and providing evidence-based solutions to address these unmet needs.

Cognoa seeks to help improve the lives and outcomes of children and their families living with behavioral health conditions. We strive to improve timely, equitable access to a diagnosis for caregivers with early concerns of developmental delay, including autism, to support opportunities for early intervention and improved outcomes for children and their families.